Midora (Amisulpride)

Amisulpride, the active ingredient in Midora, is a benzamide antipsychotic presented as an oral tablet for oral administration. It selectively blocks dopamine D2/D3 receptors and is indicated for the management of schizophrenia and depressive disorders in adult patients, helping to reduce psychotic symptoms and improve mood.

GNH USA supplies Midora as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Amisulpride is a dopamine‑blocking antipsychotic used in the treatment of psychotic and mood disorders.

Schizophrenia: reduces positive and negative symptoms and helps stabilize long‑term disease course. Depressive disorders: used as an adjunct to improve depressive symptoms in patients with mood disturbances.

Amisulpride may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or gastrointestinal discomfort. - Weight gain or changes in appetite. - Sedation or drowsiness. - Extrapyramidal symptoms such as tremor or rigidity. - Elevated prolactin levels causing menstrual changes. - Insomnia or restlessness.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome, a life‑threatening reaction. - Severe extrapyramidal reactions, including tardive dyskinesia. - QT interval prolongation leading to cardiac arrhythmias. - Agranulocytosis or severe blood dyscrasias. - Marked hyperglycemia or metabolic disturbances. - Emergence of suicidal thoughts or behaviors.

When prescribing Amisulpride, clinicians should consider several safety factors.

Renal impairment: dose adjustment may be required in reduced kidney function. Elderly patients: monitor for falls and heightened sensitivity to side effects. History of cardiac disease: perform ECG monitoring for QT prolongation. Pregnancy: use only if potential benefit justifies the risk to the fetus. Concomitant CNS depressants: caution due to additive sedation. Store at room temperature: keep in the original packaging, protect from moisture and excessive heat.

Amisulpride can interact with other medicines, influencing its safety and effectiveness.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors: may increase plasma concentrations of amisulpride. - QT‑prolonging drugs: combined effect can raise the risk of cardiac arrhythmias. - Anticholinergic agents: may exacerbate anticholinergic side effects.

Moderate Interactions (Monitor Closely): - Other antipsychotics: additive dopamine blockade may increase adverse effects. - Alcohol: can enhance sedation and impair coordination. - Antihypertensives: may potentiate hypotensive responses.